J. Goldman & Co’s Stemline Therapeutics, Inc. STML Stock Holding History

J. Goldman & Co’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-177,602	Closed	-$1.89M	–	384
2019 Q4	$1.89M	Sell	177,602 -380,794	-68%	-$3.78M	0.14%	143
2019 Q3	$5.81M	Buy	+558,396	New	+$7.31M	0.44%	74
2019 Q1	–	Sell	-225,000	Closed	-$2.14M	–	360
2018 Q4	$2.14M	Buy	225,000 +125,000	+125%	+$1.62M	0.16%	138
2018 Q3	$1.66M	Hold	100,000	–	–	0.12%	160
2018 Q2	$1.6M	Buy	100,000 +18,800	+23%	+$336K	0.08%	222
2018 Q1	$1.24M	Buy	81,200 +31,200	+62%	+$486K	0.05%	252
2017 Q4	$780K	Sell	50,000 -51,316	-51%	-$686K	0.04%	242
2017 Q3	$1.13M	Sell	101,316 -18,684	-16%	-$176K	0.06%	233
2017 Q2	$1.1M	Sell	120,000 -20,000	-14%	-$167K	0.06%	209
2017 Q1	$1.2M	Sell	140,000 -59,886	-30%	-$546K	0.06%	244
2016 Q4	$2.14M	Buy	+199,886	New	+$2.42M	0.14%	171

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

J. Goldman & Co's STML Position: Q1 2020 in Review

J. Goldman & Co sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 177,602 shares — an estimated $1.89M sold.

J. Goldman & Co first reported a position in STML in Q4 2016 and held it in 11 quarters. The position peaked at $5.81M in Q3 2019. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

J. Goldman & Co reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
J. Goldman & Co sold 177,602 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $1.89M.
J. Goldman & Co first reported a position in Stemline Therapeutics, Inc. in Q4 2016 and held it in 11 quarters.
J. Goldman & Co's Stemline Therapeutics, Inc. position peaked at $5.81M in Q3 2019.
94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on J. Goldman & Co's 13F filing for Q1 2020, filed 15 May 2020.